Skip to main content
. 2022 Apr 20;14(9):2060. doi: 10.3390/cancers14092060

Figure 2.

Figure 2

Immunotherapeutic interventions that are under investigation for treatment of recurrent thymic epithelial tumors. CTLA-4: cytotoxic T lymphocyte-associated antigen 4; PD-1: programed death-1; PD-L1: programed death-ligand 1; TGF-β: Transforming growth factor β.